Market capitalization | $1.80b |
Enterprise Value | $1.32b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.86 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-124.88m |
Free Cash Flow (TTM) Free Cash Flow | $-84.21m |
Cash position | $487.36m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
12 Analysts have issued a Disc Medicine forecast:
12 Analysts have issued a Disc Medicine forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.17 -0.17 |
67%
67%
|
|
EBITDA | -125 -125 |
51%
51%
|
EBIT (Operating Income) EBIT | -125 -125 |
50%
50%
|
Net Profit | -103 -103 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel treatments for hematologic disorders. Its programs include Bitopertin, DISC-0974, and DISC-3405. The company was founded in October 2017 and is headquartered in Watertown, MA.
Head office | United States |
CEO | John Quisel |
Employees | 74 |
Founded | 2017 |
Website | www.discmedicine.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.